| 臺大學術典藏 |
2020-03-05T06:28:37Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang Y.-H.;Lin Y.-L.;Jau-Yu Liau;Tsai J.-H.;Liang J.-T.;Lin B.-R.;Hung J.-S.;Tseng L.-H.;Lin L.-I.;Chang Y.-L.;Cheng A.-L.;Yeh K.-H.; Liang Y.-H.; Lin Y.-L.; JAU-YU LIAU; Tsai J.-H.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Tseng L.-H.; Lin L.-I.; Chang Y.-L.; Cheng A.-L.; Yeh K.-H. |
| 國立臺灣大學 |
2015 |
Cetuximab Might Be Detrimental to Metastatic Colorectal Cancer Patients with KRAS Codon 12 Mutations
|
Liang, Yi-Hsin; Lin, Yu-Lin; Liau, Jau-Yu; Tsai, Jia-Huei; Liang, Jin-Tung; Lin, Been-Ren; Hung, Ji-Shiang; Tseng, Li-Hui; Lin, Liang-In; Chang, Yih-Leong; Cheng, Ann-Lii; Yeh, Kun-Huei; 梁逸歆; 林亮音; 曾麗慧; 張逸良; 林育麟; 鄭安理; 葉坤輝; 蔡佳惠; 洪基翔; 林本仁; 廖肇裕; 梁金銅 |
| 臺大學術典藏 |
2018-09-10T15:25:12Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang, Y.-H. and Lin, Y.-L. and Liau, J.-Y. and Tsai, J.-H. and Liang, J.-T. and Lin, B.-R. and Hung, J.-S. and Tseng, L.-H. and Lin, L.-I. and Chang, Y.-L. and Cheng, A.-L. and Yeh, K.-H.; Ji-Shiang Hung |
| 臺大學術典藏 |
2020-02-25T05:15:25Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang Y.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Liang J.-T.; Lin B.-R.; JI-SHIANG HUNG; Tseng L.-H.; Lin L.-I.; Chang Y.-L.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2020-03-06T05:26:12Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang Y.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Tseng L.-H.; Lin L.-I.; YIH-LEONG CHANG; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2021-05-07T02:46:37Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
YI-HSIN LIANG; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Tseng L.-H.; Lin L.-I.; Chang Y.-L.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:50Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang Y.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Tseng L.-H.; Lin L.-I.; Chang Y.-L.; ANN-LII CHENG; Yeh K.-H. |
| 臺大學術典藏 |
2022-03-10T07:58:41Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang Y.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Liang J.-T.; Lin B.-R.; Hung J.-S.; LI-HUI TSENG; Lin L.-I.; Chang Y.-L.; Cheng A.-L.; Yeh K.-H. |
| 臺北醫學大學 |
2006 |
Cetuximab plus chemotherapy as salvage treatment for advanced colorectal cancer in Taiwanese: Experiences in Taipei Medical University Hospital
|
戴承正; Cheng-Jeng Tai; Chih-Hsiung Wu; Ching-Shyang Chen; Min-Ter Huang; Jeng-Feng Chiou; Chen-Jei Tai |
| 臺北醫學大學 |
2006 |
Cetuximab plus chemotherapy as salvage treatment for advanced colorectal cancer in Taiwanese:Experiences in Taipei Medical University Hospital
|
吳志雄; 黃銘德; Tai CJ; Wu CH; Chen CS; Huang MT; Chiou JF; Tai CJ; |
| 臺北醫學大學 |
2006 |
Cetuximab plus chemotherapy as salvage treatment for advanced colorectal cancer in Taiwanese；Experiences in Taipei Medical University Hospital
|
邱仲峰; C; J; Tai; C; H; Wu; C; S; Chen; M; T; Huang; J; F; Chiou; C; J; Tai |
| 國立成功大學 |
2024--JAN |
Cetuximab Treatment beyond Progression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Nationwide Population-Based Study (THNS-2021-08)
|
Wang;Hung-Ming;Lou;Pei-Jen;Yang;Muh-Hwa;Chen;Tein-Hua;Lien;Ming-Yu;Lin;Jin-Ching;Chen;Jo-Pai;Lu;Wei-Chen;Lu;Hsueh-Ju;Huang;Tai-Lin;Yen;Chia-Jui;Wu;Shang-Yin;Wang;Hui-Ching;Hsieh;Meng-Che |
| 高雄醫學大學 |
2007 |
Cetuximab合併化學治療於轉移性結直腸癌:表皮生長因子受器表現的角色
|
王照元 |
| 中山醫學大學 |
2021 |
Cetyltrimethylammonium Bromide Attenuates the Mesenchymal Characteristics of Hypopharyngeal Squamous Cell Carcinoma Through Inhibiting the EGFR/PI3K/AKT Signaling Pathway
|
Wu, TK; Ou, YC; Chen, YP; Huang, FM; Pan, YR; Lee, CJ |
| 中山醫學大學 |
2021 |
Cetyltrimethylammonium Bromide Disrupts Mesenchymal Characteristics of Human Tongue Squamous Cell Carcinoma SCC4 Cells Through Modulating Canonical TGF-beta/Smad/miR-181b/TIMP3 Signaling Pathway
|
Yue, CH; Chen, CH; Pan, YR; Chen, YP; Huang, FM; Lee, CJ |
| 中山醫學大學 |
2020 |
Cetyltrimethylammonium Bromide Disrupts the Mesenchymal Characteristics of HA22T/VGH Cells Via Inactivation of c-Met/PI3K/Akt/mTOR Pathway
|
Yue, CH; Chen, CH; Lee, WT; Su, TF; Pan, YR; Chen, YP; Huang, FM; Lee, CJ |
| 元智大學 |
Sep-23 |
Cetyltrimethylammonium Bromide Reformed Ceria Nanocomposites of Chemical Mechanical Planarization for Silica Wafer
|
You-Sheng Lin; Kuen-Song Lin; Wei‒Chin Tsai; Ndumiso Vukile Mdlov; Cheng-Yang Tan; U-Ser Jeng |
| 中山醫學大學 |
2020 |
Cetyltrimethylammonium Bromide Suppresses the Migration and Invasion of Hepatic Mahlavu Cells by Modulating Fibroblast Growth Factor Signaling
|
Wu, TK; Chen, CH; Lee, WT; Su, TF; Pan, YR; Huang, FM; Lee, CJ |
| 義守大學 |
2008 |
CEV過程下美式回顧型選擇權的評價
|
童三峰; San-Feng Tong |
| 臺大學術典藏 |
2018-09-10T03:46:05Z |
Cezanne: la serie de Chateau Noir
|
劉巧楣; CHIAO-MEI LIU; 劉巧楣 |
| 國立臺灣大學 |
2001-06 |
Cezanne: la serie de Chateau Noir
|
劉巧楣 |
| 中華大學 |
1998 |
CE認證專案研究-以醫療器材為例
|
許峻獻; HSUEN, HSU CHUN |
| 淡江大學 |
2011-11-05 |
CF-002 Analysis, Synthesis and Design of a One-step Dimethyl Ether Production via a Thermodynamic Approach
|
Chen, H.J.; C.W. Fan |
| 臺大學術典藏 |
2022-06-21T23:24:24Z |
CF-NET: COMPLEMENTARY FUSION NETWORK FOR ROTATION INVARIANT POINT CLOUD COMPLETION
|
Chen, Bo Fan; Yeh, Yang Ming; YI-CHANG LU |
| 中原大學 |
2003-01 |
CF/sub 4//C/sub 2/H/sub 2/電漿聚合披覆非對稱性聚[石風]薄膜應用於滲透蒸發分離程序 CF/sub 4//C/sub 2/H/sub 2/ Plasma Deposition onto Asymmetric Polysulfone Membrane for Pervaporation Separation Process
|
方佩珊;杜振源;李魁然;賴君義 |
